Drug or technology

TMS

2 developments in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

Latest

Everything in the corpus, newest first.

SEP 11, 2026 · INTERVENTIONAL STUDY

Molecular Signatures of TMS Response in Treatment-Resistant Depression

ClinicalTrials.gov

This is an active, unblinded, single-arm biomarker discovery study with no results yet reported; it aims to identify proteomic and metabolomic signatures of TMS response but has not yet yielded outcome data.

PreliminaryMajor Depression Disorder NCT07039370 TMS

Reported

Planned enrollment55

Primary outcome measure 1Plasma Proteomic Profile Changes After TMS…

Primary outcome measure 2Plasma Metabolomic Profile Changes After TM…

SEP 4, 2026 · PHASE 1/2 TRIAL

Large-coil Parietal Repetitive Transcranial Magnetic Stimulation (rTMS) for Alzheimer Disease (AD)

ClinicalTrials.gov

This is a Phase 1/2 feasibility and tolerability trial still recruiting, with no results posted; it addresses whether deep rTMS of the precuneus is safe and tolerable in Alzheimer's disease, not efficacy.

PreliminaryNCT06597942 Alzheimer&amp;#39;s Disease Alzheimer Disease

Reported

Estimated enrollment54

Primary outcome measureCompletion Rate from enrollment to end of t…

Study phasePhase 1, Phase 2